Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.52 |
| ▸ | NOS2 | P35228 | 5/20 | 0.51 |
| ▸ | NOS1 | P29475 | 4/20 | 0.51 |
| ▸ | NOS3 | P29474 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | OTC | P00480 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ARG1 | P05089 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236178 | 1.00 | KDM4E (0.56) | KDM4EMAPK1HIF1AGSRPAOX | |
| SCHEMBL919222 | 1.00 | KDM4E (0.56) | KDM4EMAPK1HIF1AGSRPAOX | |
| Hydrochloric Acid SCHEMBL28854969 | 0.98 | KDM4E (0.54) | KDM4EMAPK1HIF1AGSRPAOX | |
| SCHEMBL30125060 | 0.98 | KDM4E (0.59) | KDM4EMAPK1HIF1AGSRPAOX | |
| Hydrochloric Acid SCHEMBL15669798 | 0.98 | KDM4E (0.54) | KDM4EMAPK1HIF1AGSRPAOX | |
| Ethylene SCHEMBL28796155 | 0.96 | KDM4E (0.52) | KDM4EMAPK1HIF1AGSRPAOX | |
| SCHEMBL976174 | 0.94 | OTC (0.57) | KDM4EMAPK1HIF1AGSRPAOX | |
| SCHEMBL3503365 | 0.94 | OTC (0.57) | KDM4EMAPK1HIF1AGSRPAOX | |
| SCHEMBL2238055 | 0.94 | OTC (0.57) | KDM4EMAPK1HIF1AGSRPAOX | |
| Lysine SCHEMBL18825683 | 0.93 | GSR (0.67) | KDM4EMAPK1HIF1AGSRPAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1828 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | claimed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| EP-4587116-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| US-20250147048-A1 | METHODS OF DIAGNOSTIC SCREENING AND EARLY DETECTION OF ADENOMYOSIS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-05-08 | — | — | US | claimed |
| WO-2025081091-A1 | HETEROBIFUNCTIONAL CONDITIONAL INHIBITORS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2025054048-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING LIPID AND CHOLESTEROL METABOLISM ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2025-03-13 | — | — | WO | claimed |
| CN-119320777-A | Metabolite screening method for promoting expression of porcine intestinal defensin pBD1 and application thereof | 浙江大学 | 2025-01-17 | — | — | CN | claimed |
| EP-4457513-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2024-11-06 | — | — | EP | claimed |
| EP-4442264-A1 | THERAPEUTIC AGENT FOR DIARRHEA AND METHOD FOR TREATING BOVINE DIARRHEA | Tohoku University (JP) | 2024-10-09 | — | — | EP | claimed |
| EP-4440342-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2024-10-09 | — | — | EP | claimed |
| US-20040198959-A1 | Acetyllysine-recognizing monoclonal antibody and process for producing the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2004-10-07 | — | — | US | claimed |
| US-20040091951-A1 | Assay for measuring acetylation or deacetylation activity of an enzyme | AXYS PHARMACEUTICALS, INC. (US) | 2004-05-13 | — | — | US | claimed |
| EP-1380646-A1 | ACETYLLYSINE-RECOGNIZING MONOCLONAL ANTIBODY AND PROCESS FOR PRODUCING THE SAME | Japan Science and Technology Corporation (JP) | 2004-01-14 | — | — | EP | claimed |
| WO-2003066889-A2 | ASSAY FOR ACYTYLTRANSFERASE OR DEACETYLASE ACTIVITY | AXYS PHARMACEUTICALS, INC. (US) | 2003-08-14 | — | — | WO | claimed |
| EP-0667246-A1 | Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
| EP-0178911-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | claimed |
| US-4910296-A | Polypeptide | MAX-PLANCK-GESELLSCHAFT ZUR FOEDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1990-03-20 | — | — | US | claimed |
| US-4612365-A | Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments | MAX-PLANCK-GESELLSCHAFT ZUR FOEDERUNG DER WISSENSCHAFTEN (DE) | 1986-09-16 | — | — | US | claimed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | claimed |
| EP-0056594-B1 | THYMOSIN-ALPHA-1 FRAGMENTS AND PHARMACEUTICAL COMPOSITIONS WITH IMMUNOREGULATING ACTION CONTAINING THEM | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1984-09-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | KDM4E 4749/4885MAPK1 1738/4885HIF1A 2439/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | KDM4E 124/4885MAPK1 1697/4885HIF1A 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.